US20130028921A1 - Composition comprising coumestrol or a bean extract containing coumestrol - Google Patents
Composition comprising coumestrol or a bean extract containing coumestrol Download PDFInfo
- Publication number
- US20130028921A1 US20130028921A1 US13/637,966 US201113637966A US2013028921A1 US 20130028921 A1 US20130028921 A1 US 20130028921A1 US 201113637966 A US201113637966 A US 201113637966A US 2013028921 A1 US2013028921 A1 US 2013028921A1
- Authority
- US
- United States
- Prior art keywords
- coumestrol
- bean extract
- composition
- bean
- present disclosure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N O=C1OC2=C(C=CC(O)=C2)C2=C1C1=CC=C(O)C=C1O2 Chemical compound O=C1OC2=C(C=CC(O)=C2)C2=C1C1=CC=C(O)C=C1O2 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present disclosure relates to a composition comprising coumestrol or a bean extract comprising coumestrol.
- Bean is of great nutritional value and contains various physiologically active and functional substances. Especially, since the phytoestrogens contained in bean are similar to the estrogen of mammals including human in structure, they have the effect of preventing chronic diseases such as hormonal disorders.
- the phytoestrogens include in general isoflavone, coumestan and lignan.
- the present disclosure is directed to providing a composition for inhibiting differentiation of adipocytes, enhancing immunity, detoxifying toxic substances, and preventing or improving degenerative neurological disorders, comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- the present disclosure provides a composition for inhibiting differentiation of adipocytes comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- the present disclosure provides a composition for enhancing immunity comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- the present disclosure provides a composition for detoxifying toxic substances comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- the present disclosure provides a composition for preventing or improving degenerative neurological disorders comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- composition according to an embodiment of the present disclosure which comprises coumestrol or a bean extract comprising coumestrol as an active ingredient, has the effect of inhibiting differentiation of adipocytes, enhancing immunity, detoxifying toxic substances, and preventing or improving degenerative neurological disorders.
- the composition is useful in the field of food or medicine.
- FIG. 1 shows inhibition of adipocyte differentiation by coumestrol.
- FIG. 2 shows decreased expression of adipocyte marker genes by coumestrol.
- extract means a substance extracted from a natural substance, regardless of extraction method or ingredients.
- the term is used in a broad sense including, for example, ingredients soluble in water or an organic solvent extracted from a natural substance using the solvent, or specific ingredients of a natural substance such as oil extracted therefrom.
- the present disclosure provides a composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- Coumestrol (CMS; 3,9-dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one) has a structure of Chemical Formula 1:
- Coumestrol is one of phytoestrogens and is usually found in the seed, root or leaf of plants in the family Leguminosae or Compositae. It can be classified as a coumestan-like isoflavonoid and is known to have an estrogenic effect.
- the composition comprises coumestrol, a natural substance comprising coumestrol or an extract thereof.
- the natural substance comprising coumestrol may be one or more bean selected from soybean, pea, mung bean and sprouted beans sprouted therefrom, red clover (alfalfa), Brussels sprout, or the like.
- the natural substance comprising coumestrol may be bean.
- the bean may be any plant comprising coumestrol in the family Leguminosae, without particular limitation.
- the ban that can be used in the present disclosure may be one for bean paste, bean curd, namul, rice cooking or green bean.
- the bean varieties for bean paste or bean curd include daepung, hojang, jangwon, daehwang, sodam, songhak, daewon, jinpum, danbaek, duyu, shinpaldal, taegwang, manli, jangsu, muhan, baegun, saeal, hwangkeum and jangyeop.
- the bean varieties for namul include shinhwa, sowon, anpyeong, seonam, dachae, sorok, soho, somyeong, dawon, pungsan-namul, iksan-namul, sobaek-namul, gwangan, danyeop and eunha
- the bean varieties for rice cooking include cheongja, heukcheong, galmi, seonheuk, geomjeong-kong and ilpumgeomjeong-kong.
- the bean varieties for green bean include daol, shinrok, saeul, geomjeongeul, seokryang-putkong, hwaeom-putkong and keuneul.
- the bean may be one that can be sprouted and is resistant to damage from disease and harmful insects.
- Such bean varieties include, for example, shinhwa, sowon, anpyeong, seonam, dachae, sorok, soho, somyeong, dawon, pungsan-namul, iksan-namul, sobaek-namul, gwangan, danyeop and eunha.
- the natural substance or the extract thereof may comprise a large quantity of coumestrol. Specifically, it may comprise 0.01-50 wt %, more specifically 0.1-30 wt %, of coumestrol based on the total weight of the natural substance or the extract thereof.
- the extract of the natural substance comprising coumestrol may be obtained by extracting the natural substance comprising coumestrol with water or ethanol at normal or elevated temperature, completely concentrating the resulting extract and dispersing again in water, and fractionating with one or more solvent of equal volume selected from hexane, dichloromethane, chloroform, ethyl acetate, butanol, ethanol, methanol and water.
- the extraction method is not limited thereto and any extraction method may be employed.
- the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for enhancing immunity.
- Coumestrol enhances immunity and activates immune cells by proliferating the immune cells.
- the composition comprising coumestrol may enhance immunity and protect the body from microbes, bacteria, viruses, etc.
- the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for preventing or improving degenerative neurological disorders.
- the degenerative neurological disorders refer to the diseases occurring as a result of degenerative damage and deteriorated function of nerves or nerve cells. Examples of the degenerative neurological disorders may include glaucoma, glaucoma, myasthenia gravis, diabetic neuropathy, cerebrovascular accident, spinal cord injury, Lou Gehrig's disease (amyotrophic lateral sclerosis; ALS), Parkinson's disease, Alzheimer's disease or idiopathic dementia, but are not limited thereto.
- Coumestrol increases viability of nerve cells by protecting them from neurotoxins and scavenges reactive oxygen species produced by neurotoxins. Accordingly, the composition comprising coumestrol may prevent or improve degenerative neurological disorders by inhibiting the action of neurotoxins.
- composition according to an embodiment of the present disclosure may comprise 0.001-30 wt %, specifically 0.01-10 wt %, more specifically 0.1-5 wt %, of coumestrol or a bean extract comprising coumestrol based on the total weight of the composition.
- coumestrol or the bean extract comprising coumestrol is included in the above-described range, the intended effect of the present disclosure can be adequately achieved while both stability and safety are satisfied and favorable cost-effectiveness may be achieved.
- the present disclosure provides a food composition comprising coumestrol or a bean extract comprising coumestrol.
- the food composition may be a health food, functional food or food additive composition.
- the food composition may comprise other ingredients providing synergic effect without negatively affecting the desired effect.
- additives such as fragrance, pigment, sterilizer, antioxidant, antiseptic, moisturizer, thickener, mineral, emulsifier, synthetic polymer, etc. may be further included.
- auxiliary ingredients such as water-soluble vitamin, oil-soluble vitamin, polymer peptide, polymer polysaccharide, and seaweed extract, etc. may be further included. These ingredients may be selected by those skilled in the art without difficulty considering the particular formulation or purpose of use. The addition amount may be determined within the range not negatively affecting the purpose and effect of the present disclosure.
- the dose of the active ingredient is within the level of those skilled in the art.
- the dose may be 0.1-5000 mg/kg/day, more specifically 50-500 mg/kg/day, but is not limited thereto, and may be varied with various factors including the age, physical condition, complication, etc. of a subject to be treated.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising coumestrol or a bean extract comprising coumestrol.
- the pharmaceutical composition may further comprise a pharmaceutical adjuvant such as antiseptic, stabilizer, hydrating agent, emulsifying accelerator, salt and/or buffer for controlling osmotic pressure, etc. or other therapeutically useful substance, and may be prepared into various formulations for oral or parenteral administration.
- the formulation for oral administration may include, for example, tablet, pill, hard or soft capsule, liquid, suspension, emulsion, syrup, powder, dust, granule, pellet, or the like.
- These formulations may comprise, in addition to the active ingredient, a surfactant, a diluent (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine) or a lubricant (e.g., silica, talc, stearic acid and magnesium or calcium salt thereof or polyethylene glycol).
- a surfactant e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine
- a lubricant e.g., silica, talc, stearic acid and magnesium or calcium salt thereof or polyethylene glycol.
- the tablet may comprise a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose and polyvinylpyrrolidone, and may occasionally comprise a pharmaceutical additive such as a disintegrant, e.g. starch, agar, alginic acid or a sodium salt thereof, an absorbent, a colorant, a flavor, a sweetener, or the like.
- a disintegrant e.g. starch, agar, alginic acid or a sodium salt thereof, an absorbent, a colorant, a flavor, a sweetener, or the like.
- the tablet may be prepared according to the commonly employed mixing, granulation or coating method.
- the formulation for parenteral administration may include, for example, injection, drop, ointment, lotion, gel, cream, spray, suspension, emulsion, suppository, patch, etc., but is not limited thereto.
- a pharmaceutically acceptable amount, i.e. administration dose, of the dose of the active ingredient will vary depending on the age, sex and body weight of the subject to be treated, severity of particular disease or pathological condition to be treated, administration route and discretion of the prescriber. Those skilled in the art may determine the administration dose considering the known bioavailability of coumestrol upon oral administration (about 11.7%) as well as the above-described factors. For example, a general administration dose may be 0.01-1000 mg/kg/day, specifically 1-40 mg/kg/day. However, the described administration dose does not limit the scope of the present disclosure by any means.
- test examples are provided for illustrative purposes only and are not intended to limit the scope of the present disclosure.
- CMS coumestrol
- 3T3-L1 mouse preadipocytes CL-173, ATCC
- BBR berberine
- adipocyte differentiation was identified by staining triglycerides in the cells with Oil Red O (Sigma). The result is shown in FIG. 1 .
- the group treated with coumestrol showed less stained area than those treated with the positive control rosiglitazone or the negative control berberine. This means that adipocyte differentiation is remarkably decreased by coumestrol and the effect is superior to that of berberine.
- adipocyte-specific genes in the in the adipocytes was investigated by Q-PCR. The expression level of each group relative to the untreated group was evaluated and is shown in FIG. 2 .
- the genes tested were aP2 (fatty acid binding protein 4, adipocyte specific type), Acrp30 (adiponectin), PPAR (peroxisome proliferator-activated receptor), SREBP1c (sterol regulatory element binding protein 1c) and FAS (fatty acid synthase), which are used as molecular markers of adipocyte differentiation and fatty acid synthesis.
- coumestrol resulted in remarkably decreased mRNA expression of the molecular markers of adipocyte differentiation and fatty acid synthesis, and the effect was better than that of berberine.
- coumestrol inhibits adipocyte differentiation and fatty acid synthesis. Accordingly, the composition comprising coumestrol may prevent or improve obesity and may prevent or improve type 2 diabetes, fatty liver, cardiovascular disease, etc. caused by obesity.
- Spleen was aseptically removed from an ICR mouse sacrificed by cervical dislocation.
- the spleen was washed with an RPMI 1640 solution and lightly smashed with a sterilized glass rod to isolate the mouse spleen cells.
- a suspension of the isolated cells was passed through a 200-mesh stainless steel sieve (Sigma Chemical Co., St. Louis, Mo., USA) and centrifuged for 10 minutes at 4° C. and 3,000 rpm in a 50-mL centrifuge tube.
- the resulting cell pellets were suspended in a lysing buffer (Tris-buffered ammonium chloride; 0.87% NH 4 Cl, pH 7.2) for 5 minutes to remove red blood cells.
- Tris-buffered ammonium chloride Tris-buffered ammonium chloride; 0.87% NH 4 Cl, pH 7.2
- the cells were washed twice with RPMI by centrifugal washing, diluted to 5.0 ⁇ 10 6 cells/mL in 10%-FBS RPMI 1640, and seeded on a 96-well plate, with 90 ⁇ L per each well, for measurement of cell proliferating activity.
- the cells were cultured for 44 hours and the proliferating activity of the spleen cells was measured (CCK-8, Dojindo Laboratories, Japan). 10 ⁇ L of 10 ⁇ g/mL LPS was used as positive control.
- the immune cell proliferating activity (%) of each group relative to the untreated group was measured and is shown in Table 1.
- coumestrol promotes proliferation of immune cells, and the effect is better than that of the positive control at higher concentration. Accordingly, the composition comprising coumestrol may provide a superior effect of enhancing immunity by activating immune cells.
- HUVECs Human umbilical vein endothelial cells (HUVECs, CRL-2873, ATCC) were used to evaluate the coumestrol's effect against nicotine which is a major toxic substance included in cigarettes.
- HUVECs were cultured under the condition of 37° C. and 5% CO 2 using the microvascular endothelial cell growth medium-2 (EGM-2).
- EGM-2 microvascular endothelial cell growth medium-2
- the cells were seeded onto a 96-well plate, with 2 ⁇ 10 4 cells per well, and cultured for about 24 hours in a medium containing 10% FBS until ⁇ 80% confluency. After treating with nicotine to a final concentration of 25 mM, the cells were cultured for 24 hours with 0.1, 1 or 10 ⁇ M coumestrol, except for the negative control group.
- the viability (%) of the vascular endothelial cells was evaluated relative to the untreated group and is given in Table 2.
- coumestrol increases the viability of vascular endothelial cells by detoxifying nicotine. Accordingly, the composition comprising coumestrol may detoxify toxic substances ingested into the body and prevent or improve vascular diseases caused thereby.
- SH-SY5Y cells (CRL-2266, ATCC) were used to evaluate the coumestrol's effect of protecting nerve cells from neurotoxins.
- the cells were cultured in a medium comprising 90% DMEM, 10% fetal calf serum, 100 IU/mL penicillin and 100 pg/mL streptomycin under the condition of 37 ° C. and 5% CO 2 .
- trypsin When the cells grew confluent, they were harvested with trypsin, diluted on a 96-well plate to 1 ⁇ 10 4 cells per well, and then grafted onto a culture dish. 24 hours later, after treating the cultured cells with 0.01, 0.1 or 1 ⁇ M coumestrol, the cells were treated with 50 ⁇ M 6-OHDA 2 hours later to induce cytotoxicity.
- a negative control group was treated only with 50 ⁇ M 6-OHDA.
- the viability (%) of the nerve cells was measured by MTT assay 24 hours later and the result is shown in Table 3.
- mitochondrial potential of the cells was measured using the JC-1 fluorescent reagent (Beyotime, China). The effect of inhibiting decline of mitochondrial potential (%) is shown in Table 4.
- coumestrol increases the viability of nerve cells in the presence of neurotoxins and has an excellent effect of inhibiting decline of mitochondrial potential.
- the same cells used in Test Example 4-1 were cultured under the same condition.
- the cultured cells were treated with 0.01, 0.1 or 1 ⁇ M coumestrol and then treated with 50 ⁇ M 6-OHDA 2 hours later to induce increase of reactive oxygen species (ROS) in the cells.
- ROS reactive oxygen species
- the fluorescence intensity of DCF was measured with the Wallac VICTOR2 fluorometer (Wallac, Turku, Finland) at excitation wavelength of 485 nm and emission wavelength of 530 nm.
- ROS scavenging effect (%) relative to the negative control group was calculated from the measured fluorescence intensity. The result is given in Table 5.
- coumestrol has an excellent effect of scavenging ROS produced by neurotoxins.
- composition comprising coumestrol may prevent or improve degenerative neurological disorders by inhibiting the action of neurotoxins.
- Coumestrol 80 mg
- vitamin E 9 mg
- vitamin C 9 mg
- palm oil 2 mg
- hydrogenated vegetable oil 8 mg
- yellow beeswax 4 mg
- lecithin 9 mg
- 400 mg of the solution is filled per capsule.
- a soft capsule sheet is prepared using gelatin 66 (wt %), glycerin (24 wt %) and sorbitol (10 wt %), which is filled with the filling solution to prepare a soft capsule containing 400 mg of the composition according to the present disclosure.
- Coumestrol 80 mg
- vitamin E 9 mg
- vitamin C 9 mg
- galactooligosaccharide 200 mg
- lactose 60 mg
- maltose 140 mg
- Coumestrol 80 mg
- vitamin E 9 mg
- vitamin C 9 mg
- citric acid 0.6 g
- oligosaccharide syrup 25 g
- purified water 300 mL
- 200 mL of the resulting mixture is filled in a bottle.
- a drink is prepared by sterilizing at 130 ° C. for 4-5 seconds.
- Coumestrol 80 mg
- vitamin E 9 mg
- vitamin C 9 mg
- anhydrous crystalline glucose 250 mg
- starch 550 mg
- An injection is prepared using the above ingredients per ampule (2 mL) according to a commonly employed method.
Abstract
The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved.
Description
- The present disclosure relates to a composition comprising coumestrol or a bean extract comprising coumestrol.
- Bean is of great nutritional value and contains various physiologically active and functional substances. Especially, since the phytoestrogens contained in bean are similar to the estrogen of mammals including human in structure, they have the effect of preventing chronic diseases such as hormonal disorders. The phytoestrogens include in general isoflavone, coumestan and lignan.
- The present disclosure is directed to providing a composition for inhibiting differentiation of adipocytes, enhancing immunity, detoxifying toxic substances, and preventing or improving degenerative neurological disorders, comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- In an aspect, the present disclosure provides a composition for inhibiting differentiation of adipocytes comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- In another aspect, the present disclosure provides a composition for enhancing immunity comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- In another aspect, the present disclosure provides a composition for detoxifying toxic substances comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- In another aspect, the present disclosure provides a composition for preventing or improving degenerative neurological disorders comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- The composition according to an embodiment of the present disclosure, which comprises coumestrol or a bean extract comprising coumestrol as an active ingredient, has the effect of inhibiting differentiation of adipocytes, enhancing immunity, detoxifying toxic substances, and preventing or improving degenerative neurological disorders. The composition is useful in the field of food or medicine.
-
FIG. 1 shows inhibition of adipocyte differentiation by coumestrol. -
FIG. 2 shows decreased expression of adipocyte marker genes by coumestrol. - As used herein, “extract” means a substance extracted from a natural substance, regardless of extraction method or ingredients. The term is used in a broad sense including, for example, ingredients soluble in water or an organic solvent extracted from a natural substance using the solvent, or specific ingredients of a natural substance such as oil extracted therefrom.
- Hereinafter, the present disclosure is described in further detail.
- In an aspect, the present disclosure provides a composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
- Coumestrol (CMS; 3,9-dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one) has a structure of Chemical Formula 1:
- Coumestrol is one of phytoestrogens and is usually found in the seed, root or leaf of plants in the family Leguminosae or Compositae. It can be classified as a coumestan-like isoflavonoid and is known to have an estrogenic effect.
- In an exemplary embodiment of the present disclosure, the composition comprises coumestrol, a natural substance comprising coumestrol or an extract thereof. In another exemplary embodiment of the present disclosure, the natural substance comprising coumestrol may be one or more bean selected from soybean, pea, mung bean and sprouted beans sprouted therefrom, red clover (alfalfa), Brussels sprout, or the like. In another exemplary embodiment of the present disclosure, the natural substance comprising coumestrol may be bean.
- In an exemplary embodiment of the present disclosure, the bean may be any plant comprising coumestrol in the family Leguminosae, without particular limitation. For example, the ban that can be used in the present disclosure may be one for bean paste, bean curd, namul, rice cooking or green bean. The bean varieties for bean paste or bean curd include daepung, hojang, jangwon, daehwang, sodam, songhak, daewon, jinpum, danbaek, duyu, shinpaldal, taegwang, manli, jangsu, muhan, baegun, saeal, hwangkeum and jangyeop. The bean varieties for namul include shinhwa, sowon, anpyeong, seonam, dachae, sorok, soho, somyeong, dawon, pungsan-namul, iksan-namul, sobaek-namul, gwangan, danyeop and eunha The bean varieties for rice cooking include cheongja, heukcheong, galmi, seonheuk, geomjeong-kong and ilpumgeomjeong-kong. And, the bean varieties for green bean include daol, shinrok, saeul, geomjeongeul, seokryang-putkong, hwaeom-putkong and keuneul. In another exemplary embodiment of the present disclosure, the bean may be one that can be sprouted and is resistant to damage from disease and harmful insects. Such bean varieties include, for example, shinhwa, sowon, anpyeong, seonam, dachae, sorok, soho, somyeong, dawon, pungsan-namul, iksan-namul, sobaek-namul, gwangan, danyeop and eunha.
- In an exemplary embodiment of the present disclosure, the natural substance or the extract thereof may comprise a large quantity of coumestrol. Specifically, it may comprise 0.01-50 wt %, more specifically 0.1-30 wt %, of coumestrol based on the total weight of the natural substance or the extract thereof.
- In an exemplary embodiment of the present disclosure, the extract of the natural substance comprising coumestrol may be obtained by extracting the natural substance comprising coumestrol with water or ethanol at normal or elevated temperature, completely concentrating the resulting extract and dispersing again in water, and fractionating with one or more solvent of equal volume selected from hexane, dichloromethane, chloroform, ethyl acetate, butanol, ethanol, methanol and water. However, the extraction method is not limited thereto and any extraction method may be employed.
- In an exemplary embodiment of the present disclosure, the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for inhibiting differentiation of adipocytes. Coumestrol inhibits differentiation of adipocytes and decreases mRNA expression of molecular markers of adipocyte differentiation and fatty acid synthesis. Accordingly, the composition comprising coumestrol may inhibit differentiation of adipocytes and prevent or improve obesity and various diseases induced by obesity. Examples of such diseases include type 2 diabetes, fatty liver or cardiovascular diseases, but are not limited thereto. The cardiovascular disease includes one or more of hyperlipidemia, hypertension, angina, myocardial infarction and arteriosclerosis.
- In an exemplary embodiment of the present disclosure, the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for enhancing immunity. Coumestrol enhances immunity and activates immune cells by proliferating the immune cells. Accordingly, the composition comprising coumestrol may enhance immunity and protect the body from microbes, bacteria, viruses, etc.
- In an exemplary embodiment of the present disclosure, the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for detoxifying toxic substances. The composition may detoxify toxic substances ingested into the body. Particularly, it has an excellent ability of detoxifying nicotine. Nicotine is an addiction-inducing substance contained in cigarettes and may cause negative cardiovascular effects by stimulating the sympathetic nervous system. Coumestrol increases viability of vascular endothelial cells by protecting the vascular endothelial cells from nicotine or other toxic substances. Accordingly, the composition comprising coumestrol may detoxify nicotine or other toxic substances ingested into the body and prevent or improve vascular diseases caused by the toxic substances. Examples of the vascular diseases may include blood circulation disorder, hypertension or arteriosclerosis, but are not limited thereto.
- In an exemplary embodiment of the present disclosure, the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for preventing or improving degenerative neurological disorders. The degenerative neurological disorders refer to the diseases occurring as a result of degenerative damage and deteriorated function of nerves or nerve cells. Examples of the degenerative neurological disorders may include glaucoma, glaucoma, myasthenia gravis, diabetic neuropathy, cerebrovascular accident, spinal cord injury, Lou Gehrig's disease (amyotrophic lateral sclerosis; ALS), Parkinson's disease, Alzheimer's disease or idiopathic dementia, but are not limited thereto. Coumestrol increases viability of nerve cells by protecting them from neurotoxins and scavenges reactive oxygen species produced by neurotoxins. Accordingly, the composition comprising coumestrol may prevent or improve degenerative neurological disorders by inhibiting the action of neurotoxins.
- The composition according to an embodiment of the present disclosure may comprise 0.001-30 wt %, specifically 0.01-10 wt %, more specifically 0.1-5 wt %, of coumestrol or a bean extract comprising coumestrol based on the total weight of the composition. When the coumestrol or the bean extract comprising coumestrol is included in the above-described range, the intended effect of the present disclosure can be adequately achieved while both stability and safety are satisfied and favorable cost-effectiveness may be achieved.
- In another aspect, the present disclosure provides a food composition comprising coumestrol or a bean extract comprising coumestrol. The food composition may be a health food, functional food or food additive composition. The food composition may comprise other ingredients providing synergic effect without negatively affecting the desired effect. For example, additives such as fragrance, pigment, sterilizer, antioxidant, antiseptic, moisturizer, thickener, mineral, emulsifier, synthetic polymer, etc. may be further included. In addition, auxiliary ingredients such as water-soluble vitamin, oil-soluble vitamin, polymer peptide, polymer polysaccharide, and seaweed extract, etc. may be further included. These ingredients may be selected by those skilled in the art without difficulty considering the particular formulation or purpose of use. The addition amount may be determined within the range not negatively affecting the purpose and effect of the present disclosure.
- The composition according to the present disclosure may be prepared into various formulations including solution, emulsion, viscous mixture, tablet, powder, etc.
- Determination of the dose of the active ingredient is within the level of those skilled in the art. For example, the dose may be 0.1-5000 mg/kg/day, more specifically 50-500 mg/kg/day, but is not limited thereto, and may be varied with various factors including the age, physical condition, complication, etc. of a subject to be treated.
- In another aspect, the present disclosure provides a pharmaceutical composition comprising coumestrol or a bean extract comprising coumestrol. The pharmaceutical composition may further comprise a pharmaceutical adjuvant such as antiseptic, stabilizer, hydrating agent, emulsifying accelerator, salt and/or buffer for controlling osmotic pressure, etc. or other therapeutically useful substance, and may be prepared into various formulations for oral or parenteral administration.
- The formulation for oral administration may include, for example, tablet, pill, hard or soft capsule, liquid, suspension, emulsion, syrup, powder, dust, granule, pellet, or the like. These formulations may comprise, in addition to the active ingredient, a surfactant, a diluent (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine) or a lubricant (e.g., silica, talc, stearic acid and magnesium or calcium salt thereof or polyethylene glycol). The tablet may comprise a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose and polyvinylpyrrolidone, and may occasionally comprise a pharmaceutical additive such as a disintegrant, e.g. starch, agar, alginic acid or a sodium salt thereof, an absorbent, a colorant, a flavor, a sweetener, or the like. The tablet may be prepared according to the commonly employed mixing, granulation or coating method.
- The formulation for parenteral administration may include, for example, injection, drop, ointment, lotion, gel, cream, spray, suspension, emulsion, suppository, patch, etc., but is not limited thereto.
- A pharmaceutically acceptable amount, i.e. administration dose, of the dose of the active ingredient will vary depending on the age, sex and body weight of the subject to be treated, severity of particular disease or pathological condition to be treated, administration route and discretion of the prescriber. Those skilled in the art may determine the administration dose considering the known bioavailability of coumestrol upon oral administration (about 11.7%) as well as the above-described factors. For example, a general administration dose may be 0.01-1000 mg/kg/day, specifically 1-40 mg/kg/day. However, the described administration dose does not limit the scope of the present disclosure by any means.
- The features and effects of the present disclosure will be described in detail through test examples. However, the following test examples are provided for illustrative purposes only and are not intended to limit the scope of the present disclosure.
- In order to evaluate the coumestrol's effect of inhibiting adipocyte differentiation, 10 M coumestrol (CMS) was administered continuously while 3T3-L1 mouse preadipocytes (CL-173, ATCC) were differentiated into adipocytes. 1 M Rosiglitazone (Rosi), which is known to promote adipocyte differentiation, was used as positive control and 10 M berberine (BBR), which is known to inhibit adipocyte differentiation, was used as negative control. On the day when adipocyte differentiation was started and on days 2, 4 and 6, the test substance was administered and the medium was changed. The adipocyte differentiation was carried out for about 7 days when the adipocyte differentiation was completed in the positive control group.
- Then, differentiation of adipocytes was identified by staining triglycerides in the cells with Oil Red O (Sigma). The result is shown in
FIG. 1 . As seen fromFIG. 1 , the group treated with coumestrol showed less stained area than those treated with the positive control rosiglitazone or the negative control berberine. This means that adipocyte differentiation is remarkably decreased by coumestrol and the effect is superior to that of berberine. - Also, expression of adipocyte-specific genes in the in the adipocytes was investigated by Q-PCR. The expression level of each group relative to the untreated group was evaluated and is shown in
FIG. 2 . The genes tested were aP2 (fatty acid binding protein 4, adipocyte specific type), Acrp30 (adiponectin), PPAR (peroxisome proliferator-activated receptor), SREBP1c (sterol regulatory element binding protein 1c) and FAS (fatty acid synthase), which are used as molecular markers of adipocyte differentiation and fatty acid synthesis. As seen fromFIG. 2 , coumestrol resulted in remarkably decreased mRNA expression of the molecular markers of adipocyte differentiation and fatty acid synthesis, and the effect was better than that of berberine. - Thus, coumestrol inhibits adipocyte differentiation and fatty acid synthesis. Accordingly, the composition comprising coumestrol may prevent or improve obesity and may prevent or improve type 2 diabetes, fatty liver, cardiovascular disease, etc. caused by obesity.
- Spleen was aseptically removed from an ICR mouse sacrificed by cervical dislocation. The spleen was washed with an RPMI 1640 solution and lightly smashed with a sterilized glass rod to isolate the mouse spleen cells. A suspension of the isolated cells was passed through a 200-mesh stainless steel sieve (Sigma Chemical Co., St. Louis, Mo., USA) and centrifuged for 10 minutes at 4° C. and 3,000 rpm in a 50-mL centrifuge tube. The resulting cell pellets were suspended in a lysing buffer (Tris-buffered ammonium chloride; 0.87% NH4Cl, pH 7.2) for 5 minutes to remove red blood cells. The cells were washed twice with RPMI by centrifugal washing, diluted to 5.0×106cells/mL in 10%-FBS RPMI 1640, and seeded on a 96-well plate, with 90 μL per each well, for measurement of cell proliferating activity. After preparing a stock solution such that the final concentration of coumestrol was 0.1 or 1 μM and adding 10 μL to each well, the cells were cultured for 44 hours and the proliferating activity of the spleen cells was measured (CCK-8, Dojindo Laboratories, Japan). 10 μL of 10 μg/mL LPS was used as positive control. The immune cell proliferating activity (%) of each group relative to the untreated group was measured and is shown in Table 1.
-
TABLE 1 Immune cell proliferating activity (%) Untreated 100 LPS, 10 μg/mL (positive control) 275 Coumestrol, 0.1 μM 278 Coumestrol, 1 μM 283 - As seen from Table 1, coumestrol promotes proliferation of immune cells, and the effect is better than that of the positive control at higher concentration. Accordingly, the composition comprising coumestrol may provide a superior effect of enhancing immunity by activating immune cells.
- Human umbilical vein endothelial cells (HUVECs, CRL-2873, ATCC) were used to evaluate the coumestrol's effect against nicotine which is a major toxic substance included in cigarettes. HUVECs were cultured under the condition of 37° C. and 5% CO2 using the microvascular endothelial cell growth medium-2 (EGM-2). The cells were seeded onto a 96-well plate, with 2×104 cells per well, and cultured for about 24 hours in a medium containing 10% FBS until ˜80% confluency. After treating with nicotine to a final concentration of 25 mM, the cells were cultured for 24 hours with 0.1, 1 or 10 μM coumestrol, except for the negative control group. The viability (%) of the vascular endothelial cells was evaluated relative to the untreated group and is given in Table 2.
-
TABLE 2 Viability of vascular endothelial cells (%) Untreated 100 Negative control 55.1 Coumestrol, 0.1 μM 67.2 Coumestrol, 1 μM 72.2 Coumestrol, 10 μM 88.9 - As seen from Table 2, coumestrol increases the viability of vascular endothelial cells by detoxifying nicotine. Accordingly, the composition comprising coumestrol may detoxify toxic substances ingested into the body and prevent or improve vascular diseases caused thereby.
- 1. Evaluation of Effect of Protecting Nerve Cells from Neurotoxins
- SH-SY5Y cells (CRL-2266, ATCC) were used to evaluate the coumestrol's effect of protecting nerve cells from neurotoxins. The cells were cultured in a medium comprising 90% DMEM, 10% fetal calf serum, 100 IU/mL penicillin and 100 pg/mL streptomycin under the condition of 37 ° C. and 5% CO2. When the cells grew confluent, they were harvested with trypsin, diluted on a 96-well plate to 1×104 cells per well, and then grafted onto a culture dish. 24 hours later, after treating the cultured cells with 0.01, 0.1 or 1 μM coumestrol, the cells were treated with 50 μM 6-OHDA 2 hours later to induce cytotoxicity. A negative control group was treated only with 50 μM 6-OHDA. The viability (%) of the nerve cells was measured by MTT assay 24 hours later and the result is shown in Table 3. Also, mitochondrial potential of the cells was measured using the JC-1 fluorescent reagent (Beyotime, China). The effect of inhibiting decline of mitochondrial potential (%) is shown in Table 4.
-
TABLE 3 Viability of nerve cells (%) Untreated 100 Negative control (50 μM 6-OHDA) 78.6 Coumestrol, 0.01 μM 94.4 Coumestrol, 0.1 μM 96.5 Coumestrol, 1 μM 98.2 -
TABLE 4 Effect of inhibiting decline of mitochondrial potential (%) Negative control (50 μM 6-OHDA) 0 Coumestrol, 0.01 μM 13.2 Coumestrol, 0.1 μM 29.1 Coumestrol, 1 μM 43.0 - As seen from Tables 3 and 4, coumestrol increases the viability of nerve cells in the presence of neurotoxins and has an excellent effect of inhibiting decline of mitochondrial potential.
- 2. Evaluation of Effect of Scavenging Reactive Oxygen Species Produced by Neurotoxins
- The same cells used in Test Example 4-1 were cultured under the same condition. The cultured cells were treated with 0.01, 0.1 or 1 μM coumestrol and then treated with 50 μM 6-OHDA 2 hours later to induce increase of reactive oxygen species (ROS) in the cells. After culturing the cells for 6 hours in an incubator, the quantity of ROS in the cells was measured using DCFH-DA and the decrease of the ROS was evaluated relative to the negative control group. The fluorescence intensity of DCF was measured with the Wallac VICTOR2 fluorometer (Wallac, Turku, Finland) at excitation wavelength of 485 nm and emission wavelength of 530 nm. ROS scavenging effect (%) relative to the negative control group was calculated from the measured fluorescence intensity. The result is given in Table 5.
-
TABLE 5 ROS scavenging effect (%) Negative control (50 μM 6-OHDA) 0 Coumestrol, 0.01 μM 73.0 Coumestrol, 0.1 μM 86.7 Coumestrol, 1 μM 93.5 - As seen from Table 5, coumestrol has an excellent effect of scavenging ROS produced by neurotoxins.
- Accordingly, the composition comprising coumestrol may prevent or improve degenerative neurological disorders by inhibiting the action of neurotoxins.
- Formulation examples of the composition according to the present disclosure are described hereinafter. However, the scope of the present disclosure is not limited to the following examples.
- Coumestrol (80 mg), vitamin E (9 mg), vitamin C (9 mg), palm oil (2 mg), hydrogenated vegetable oil (8 mg), yellow beeswax (4 mg) and lecithin (9 mg) are mixed and prepared into a soft capsule filling solution according to a commonly employed method. 400 mg of the solution is filled per capsule. Separately from this, a soft capsule sheet is prepared using gelatin 66 (wt %), glycerin (24 wt %) and sorbitol (10 wt %), which is filled with the filling solution to prepare a soft capsule containing 400 mg of the composition according to the present disclosure.
- Coumestrol (80 mg), vitamin E (9 mg), vitamin C (9 mg), galactooligosaccharide (200 mg), lactose (60 mg) and maltose (140 mg) are mixed and granulated using a fluidized bed dryer. After adding sugar ester (6 mg), the resulting composition (500 mg) is prepared into a tablet according to a commonly employed method.
- Coumestrol (80 mg), vitamin E (9 mg), vitamin C (9 mg), glucose (10 g), citric acid (0.6 g) and oligosaccharide syrup (25 g) are mixed. After adding purified water (300 mL), 200 mL of the resulting mixture is filled in a bottle. Then, a drink is prepared by sterilizing at 130 ° C. for 4-5 seconds.
- Coumestrol (80 mg), vitamin E (9 mg), vitamin C (9 mg), anhydrous crystalline glucose (250 mg) and starch (550 mg) are mixed, granulated using a fluidized bed granulator, and then filled in a pouch.
-
-
Coumestrol 20 mg Sterilized distilled water for injection adequate pH adjuster adequate - An injection is prepared using the above ingredients per ampule (2 mL) according to a commonly employed method.
- Those skilled in the art will appreciate that the present disclosure may be changed and modified variously within the scope of the present disclosure.
Claims (14)
1. A method for inhibiting differentiation of adipocytes comprising administering an effective amount coumestrol or a bean extract comprising coumestrol to a subject in such need to activate mitochondria.
2. The method according to claim 1 , wherein the coumestrol or bean extract comprising coumestrol prevents or improves one or more of obesity, type 2 diabetes and fatty liver.
3. The method according to claim 1 , wherein the coumestrol or bean extract comprising coumestrol prevents or improves cardiovascular diseases induced by obesity.
4. The method according to claim 3 , wherein the cardiovascular disease comprises one or more of hyperlipidemia, hypertension, angina, myocardial infarction and arteriosclerosis.
5. A method for enhancing immunity comprising administering an effective amount of coumestrol or a bean extract comprising coumestrol to a subject in such need.
6. The method according to claim 5 , wherein the coumestrol or bean extract comprising coumestrol activates immune cells.
7. A method for detoxifying toxic substances comprising administering an effective amount of coumestrol or a bean extract comprising coumestrol to a subject in such need to detoxify toxic substances.
8. The method according to claim 7 , wherein the coumestrol or bean extract comprising coumestrol detoxifies nicotine.
9. The method according to claim 7 , wherein the coumestrol or bean extract comprising coumestrol prevents or improves vascular diseases caused by toxic substances.
10. The method according to claim 9 , wherein the vascular disease comprises one or more of blood circulation disorder, hypertension and arteriosclerosis.
11. A method for preventing or improving degenerative neurological disorders comprising administering an effective amount of coumestrol or a bean extract comprising coumestrol to a subject in such need to prevent or improve degenerative neurological disorders.
12. The method according to claim 11 , wherein the coumestrol or bean extract comprising coumestrol inhibits the action of neurotoxins.
13. The method according to claim 11 , wherein the degenerative neurological disorder comprises one or more of dementia, Alzheimer's disease and Parkinson's disease.
14-15. (canceled)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0029220 | 2010-03-31 | ||
KR20100029220 | 2010-03-31 | ||
PCT/KR2011/002233 WO2011122879A2 (en) | 2010-03-31 | 2011-03-31 | Composition comprising coumestrol or a bean extract containing coumestrol |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/002233 A-371-Of-International WO2011122879A2 (en) | 2010-03-31 | 2011-03-31 | Composition comprising coumestrol or a bean extract containing coumestrol |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/200,070 Division US20140187621A1 (en) | 2010-03-31 | 2014-03-07 | Composition comprising coumestrol or a bean extract containing coumestrol |
US14/200,079 Division US9655878B2 (en) | 2010-03-31 | 2014-03-07 | Composition comprising coumestrol or a bean extract containing coumestrol |
US14/200,064 Division US20140187620A1 (en) | 2010-03-31 | 2014-03-07 | Composition comprising coumestrol or a bean extract containing coumestrol |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130028921A1 true US20130028921A1 (en) | 2013-01-31 |
Family
ID=44712773
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/637,966 Abandoned US20130028921A1 (en) | 2010-03-31 | 2011-03-31 | Composition comprising coumestrol or a bean extract containing coumestrol |
US14/200,070 Abandoned US20140187621A1 (en) | 2010-03-31 | 2014-03-07 | Composition comprising coumestrol or a bean extract containing coumestrol |
US14/200,079 Active 2031-04-25 US9655878B2 (en) | 2010-03-31 | 2014-03-07 | Composition comprising coumestrol or a bean extract containing coumestrol |
US14/200,064 Abandoned US20140187620A1 (en) | 2010-03-31 | 2014-03-07 | Composition comprising coumestrol or a bean extract containing coumestrol |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/200,070 Abandoned US20140187621A1 (en) | 2010-03-31 | 2014-03-07 | Composition comprising coumestrol or a bean extract containing coumestrol |
US14/200,079 Active 2031-04-25 US9655878B2 (en) | 2010-03-31 | 2014-03-07 | Composition comprising coumestrol or a bean extract containing coumestrol |
US14/200,064 Abandoned US20140187620A1 (en) | 2010-03-31 | 2014-03-07 | Composition comprising coumestrol or a bean extract containing coumestrol |
Country Status (4)
Country | Link |
---|---|
US (4) | US20130028921A1 (en) |
KR (1) | KR101384497B1 (en) |
CN (3) | CN103961397A (en) |
WO (1) | WO2011122879A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016526019A (en) * | 2013-05-06 | 2016-09-01 | 株式会社アモーレパシフィックAmorepacific Corporation | Composition for preventing and treating climacteric symptoms comprising soybean extract containing cumestrol as active ingredient |
JP2022509002A (en) * | 2018-10-10 | 2022-01-20 | アモーレパシフィック コーポレーション | Composition and method of applying it to the skin to inhibit cortisone reductase |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108430486B (en) * | 2015-10-30 | 2022-05-10 | 株式会社Hubio | Sprouted fermented bean extract containing coumestrol and composition containing the same |
KR102249710B1 (en) * | 2017-10-20 | 2021-05-10 | (주)아모레퍼시픽 | Composition for preventing hair loss and promoting hair growth comprising bean tissue cultured extract and mathod for preparing the same |
JP6390805B1 (en) * | 2018-01-09 | 2018-09-19 | アルス株式会社 | Reflective optical element and interferometer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001003716A1 (en) * | 1999-07-09 | 2001-01-18 | Sun Farm Corporation | Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
US20050032882A1 (en) * | 2002-03-06 | 2005-02-10 | Sophie Chen | Botanical extract compositions and methods of use |
US20120289714A1 (en) * | 2010-01-29 | 2012-11-15 | Amorepacific Corporation | Method for preparing coumestrol and coumestrol prepared by same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6334998B1 (en) * | 1999-12-07 | 2002-01-01 | Parker Hughes Institute | Estrogens for treating ALS |
DE60313754T2 (en) | 2002-03-06 | 2008-01-24 | The Medical Research and Education Trust, San Diego | BOTANICAL EXTRACT WITH ANTICIPATIVE ACTIVITY INCLUDING ISOLIQUIRITIGENIN |
CN1984648A (en) * | 2003-03-06 | 2007-06-20 | 医学研究和教育联合企业 | Botanical extract compositions and methods of use |
US20050118290A1 (en) | 2003-12-02 | 2005-06-02 | University Of Singapore | Compositions and method for treatment of steroid/nuclear receptor-mediated diseases |
KR100706279B1 (en) * | 2005-11-11 | 2007-04-12 | (주)아모레퍼시픽 | Medicine and food compositions for improvement of obesity |
KR100701269B1 (en) * | 2006-12-19 | 2007-03-29 | (주)아모레퍼시픽 | Medicine and Food Compositions for Improvement of Obesity |
-
2011
- 2011-03-31 CN CN201410212593.8A patent/CN103961397A/en active Pending
- 2011-03-31 KR KR1020110029587A patent/KR101384497B1/en active IP Right Grant
- 2011-03-31 CN CN201510202822.2A patent/CN104771395A/en active Pending
- 2011-03-31 CN CN201180027113.5A patent/CN102905715B/en active Active
- 2011-03-31 US US13/637,966 patent/US20130028921A1/en not_active Abandoned
- 2011-03-31 WO PCT/KR2011/002233 patent/WO2011122879A2/en active Application Filing
-
2014
- 2014-03-07 US US14/200,070 patent/US20140187621A1/en not_active Abandoned
- 2014-03-07 US US14/200,079 patent/US9655878B2/en active Active
- 2014-03-07 US US14/200,064 patent/US20140187620A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001003716A1 (en) * | 1999-07-09 | 2001-01-18 | Sun Farm Corporation | Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
US20050032882A1 (en) * | 2002-03-06 | 2005-02-10 | Sophie Chen | Botanical extract compositions and methods of use |
US20120289714A1 (en) * | 2010-01-29 | 2012-11-15 | Amorepacific Corporation | Method for preparing coumestrol and coumestrol prepared by same |
Non-Patent Citations (2)
Title |
---|
Schoenroth et al., The effect of the phytoestrogen coumestrol on the NZB/W F1 murine model of systemic lupus, Journal of Autoimmunity, 2004, Vol. 23, pp. 323-332 * |
Verified Casein Diet 10 1F 5K96. Datasheet [online]. LabDiet, 2015 [retrieved 2017-02-07]. Retrieved from the Internet:<URL: http://www.labdiet.com/cs/groups/lolweb/@labdiet/documents/web_content/mdrf/mdi4/~edisp/ducm04_028427.pdf>. * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016526019A (en) * | 2013-05-06 | 2016-09-01 | 株式会社アモーレパシフィックAmorepacific Corporation | Composition for preventing and treating climacteric symptoms comprising soybean extract containing cumestrol as active ingredient |
EP2995304A4 (en) * | 2013-05-06 | 2017-01-25 | Amorepacific Corporation | Composition for preventing or treating symptoms of menopause comprising soybean extract comprising coumestrol as an active ingredient |
US10111856B2 (en) | 2013-05-06 | 2018-10-30 | Amorepacific Corporation | Composition for preventing or treating climacteric symptoms comprising soybean extract comprising coumestrol as an active ingredient |
US10959981B2 (en) | 2013-05-06 | 2021-03-30 | Amorepacific Corporation | Composition for preventing or treating climacteric symptoms comprising soybean extract comprising coumestrol as an active ingredient |
JP2022509002A (en) * | 2018-10-10 | 2022-01-20 | アモーレパシフィック コーポレーション | Composition and method of applying it to the skin to inhibit cortisone reductase |
Also Published As
Publication number | Publication date |
---|---|
CN102905715A (en) | 2013-01-30 |
US9655878B2 (en) | 2017-05-23 |
US20140187622A1 (en) | 2014-07-03 |
WO2011122879A2 (en) | 2011-10-06 |
CN104771395A (en) | 2015-07-15 |
US20140187621A1 (en) | 2014-07-03 |
CN103961397A (en) | 2014-08-06 |
KR101384497B1 (en) | 2014-04-10 |
CN102905715B (en) | 2015-10-14 |
WO2011122879A3 (en) | 2012-05-03 |
KR20110110054A (en) | 2011-10-06 |
US20140187620A1 (en) | 2014-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210401916A1 (en) | Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract | |
CN1124134C (en) | Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, ihibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent | |
US9655878B2 (en) | Composition comprising coumestrol or a bean extract containing coumestrol | |
KR101997060B1 (en) | Composition for prevention or treatment of muscular disorder, or improvement of muscular functions comprising fermented deer antler | |
KR101800632B1 (en) | Pharmaceutical composition, food composition or food additives for prevention, improvement or treatment of muscle loss, weakening, and atrophy comprising Enterococcus faecalis, it culture broth or heat killed Enterococcus faecalis as an active ingredient | |
US8168237B2 (en) | Medicinal herbal extract having anti-obesity effect | |
US11771726B2 (en) | Composition, containing Quisqualis indica extract, for preventing or treating prostatic hyperplasia | |
KR20170005632A (en) | A composition comprising extract of Elaeagnus multiflora Thunb. for preventing or treating obesity or hyperlipidemia | |
KR101269208B1 (en) | Composition comprising sauchinone as an active ingredient for preventing or treating insulin resistance | |
CN1124133C (en) | Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent | |
RU2668135C1 (en) | Pharmaceutical composition for the treatment and prevention of degenerative neurological disorders which comprises, as an active ingredient, a mixed root extract of the tree peony root, the root of dahuric angelica and the root of thorowax or its fraction | |
KR101497109B1 (en) | Composition for preventing, improving, or treating a disease controlled by PPAR action | |
KR101559483B1 (en) | Neuroprotective composition comprising extracts or fractions of seaweed as an active ingredient | |
KR102292696B1 (en) | Locusta Migratoria ethanol extract for inhibiting osteoclast differentiation and uses therof | |
KR20050047579A (en) | Bone disease drug composition using herb medicines | |
US20050048135A1 (en) | Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect | |
KR102249795B1 (en) | Composition for Improving Obesity or Exercise Performance comprising Extract from Inula japonica | |
WO2008007880A1 (en) | A composition comprising an extract of prunus persica (l.) batsch for treating and preventing bone diseases | |
KR20200129596A (en) | Composition for Preventing or Treating of Degenerative Brain Disease Comprising Extract of Zanthoxylum piperitum Fruit | |
KR102517662B1 (en) | Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising chaga | |
EP3578587B1 (en) | Novel compound hexadecaphlorethol isolated from ishige okamurae and use thereof | |
KR102113563B1 (en) | Composition for prevention and treatment of muscle disease, improvement of muscle function or enhancement of exercise performance comprising hydrangenol | |
KR20180034874A (en) | Composition for Preventing or Treating Muscle Diseases Comprising Catechins Green Tea Extracts | |
KR20220084817A (en) | Anti-obese composition comprising water extract of Gymnaster koraiensis | |
KR101413584B1 (en) | A composition for preventing and treating bone diseases containing desmodii herba extracts as a active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AMOREPACIFIC CORPORATION, KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JEON, HEE YOUNG;SHIN, HYUN JUNG;SEO, DAE BANG;AND OTHERS;REEL/FRAME:029040/0892 Effective date: 20120924 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |